Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 1040-1045

  Liu, Han Qiang ^a,b   An, Jia Ze ^c   Liu, Juan ^a   Yang, Ye Fa ^d   Zhang, Hong Xin ^e   Zhao, Bin Yu ^e   Li, Ji Bin ^a   Yang, Hu Shan ^f   Chen, Zhi Nan ^a   Xing, Jin Liang ^a  

^a State Key Laboratory of Cancer Biology   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LEUKOCYTE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELATIVE TELOMERE LENGTH; SURVIVAL TIME; TELOMERE HOMEOSTASIS;

EID: 84860469034     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs098     Document Type: Article

References (32)

1. Bisoffi, M. et al. (2006) Telomeres: prognostic markers for solid tumors. Int. J. Cancer, 119, 2255-2260.
2. Jang, J.S. et al. (2008) Telomere length and the risk of lung cancer. Cancer Sci., 99, 1385-1389.
3. Wu, X. et al. (2003) Telomere dysfunction: a potential cancer predisposition factor. J. Natl Cancer Inst., 95, 1211-1218.
4. Liu, X. et al. (2009) Constitutive telomere length and gastric cancer risk: case-control analysis in Chinese Han population. Cancer Sci., 100, 1300-1305.
5. Han, J. et al. (2009) A prospective study of telomere length and the risk of skin cancer. J. Invest. Dermatol., 129, 415-421.
6. Lan, Q. et al. (2009) A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin. Cancer Res., 15, 7429-7433.
7. Gramatges, M.M. et al. (2010) Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol. Biomarkers Prev., 19, 605-613.
8. Svenson, U. et al. (2008) Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res., 68, 3618-3623.
9. Svenson, U. et al. (2009) Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res., 69, 2896-2901.
10. Tang, Z.Y. et al. (2004) A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 130, 187-196.
11. Vogl, T.J. et al. (2009) Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur. J. Radiol., 72, 505-516.
12. Yokota, T. et al. (2003) Telomere length variation and maintenance in hepatocarcinogenesis. Cancer, 98, 110-118.
13. Oh, B.K. et al. (2008) High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab. Invest., 88, 144-152.
14. Liu, J. et al. (2011) Longer leukocyte telomere length predicts increased risk of hepatitis B virus-hyphen;related hepatocellular carcinoma: a case-control analysis. Cancer, 117, 4247-4256.
15. Yokokawa, J. et al. (2008) Enhanced functionality of CD4+ CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin. Cancer Res., 14, 1032-1040.
16. Deng, Y. et al. (2008) Telomere dysfunction and tumour suppression: the senescence connection. Nat. Rev. Cancer, 8, 450-458.
17. Soler, D. et al. (2005) Telomere dysfunction drives chromosomal instability in human mammary epithelial cells. Genes Chromosomes Cancer, 44, 339-350.
18. Silva, A.G. et al. (2010) Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia, 12, 11-19.
19. Feldser, D.M. et al. (2007) Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell, 11, 461-469.
20. Yoon, S.Y. et al. (2007) Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity. Acta Haematol., 118, 30-37.
21. Svenson, U. et al. (2009) Telomere length as a biological marker in malignancy. Biochim. Biophys. Acta, 1792, 317-323.
22. Liu, Z. et al. (2009) Tumor regulatory T cells potently abrogate antitumor immunity. J. Immunol., 182, 6160-6167.
23. Hori, S. et al. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-1061.
24. Fu, J. et al. (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 132, 2328-2339.
25. Shao, Y.Y. et al. (2011) Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. Anticancer Res., 31, 4007-4011.
26. Yang, G.L. et al. (2009) Association between CD4+CD25+Foxp3+ regulatory T cells and serum transforming growth factor beta 1 in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi, 17, 831-834.
27. Allsopp, R.C. et al. (1992) Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl Acad. Sci. USA, 89, 10114-10118.
28. Valdes, A.M. et al. (2005) Obesity, cigarette smoking, and telomere length in women. Lancet, 366, 662-664.
29. Cawthon, R.M. et al. (2003) Association between telomere length in blood and mortality in people aged 60 years or older. Lancet, 361, 393-395.
30. Huang, G.T. et al. (1998) Telomerase activity and telomere length in human hepatocellular carcinoma. Eur. J. Cancer, 34, 1946-1949.
31. Shi, G.M. et al. (2010) CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology, 52, 183-196.
32. Yang, X.R. et al. (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 59, 953-962.